Compare Moderna, Inc. (MRNA) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance

Moderna, Inc.Trade

Vanguard Short Term Corporate Bond ETFTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs Vanguard Short Term Corporate Bond ETF — how do they compare? Moderna, Inc. trades at $59.72 (market cap $23.60B), while Vanguard Short Term Corporate Bond ETF trades at $78.58. The key difference: Moderna, Inc. is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.

	MRNA	VCSH
Market Cap	$23.60B	—
Sector	Health	Fixed Income
52-Week High	$81.80	$80.20
52-Week Low	$22.36	$78.45
Enterprise Value	$19.70B	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRNA

ARKG and GNOM ETFs offer different genomic bets with varied risk and returns in 2026.24/7 Wall Street · 13 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral View details →

VCSH

View details →

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

About Vanguard Short Term Corporate Bond ETF

VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.